Vistagen Therapeutics, Inc. VTGN
0.19 USD 0.00 (+2.57%)
At closeNov 12, 2026, 4:00 AM EST
0.19 +0.01 +3.57%
Pre-market · Nov 12, 4:00 AM ET
0.1802 Day range 0.1893
0.16 52-week range 5.14
- YTD
- -71.55%
- 1 year
- -95.39%
News
defenseworld.net VistaGen Therapeutics (VTGN) Projected to Post Quarterly Earnings on Thursday VistaGen Therapeutics (NASDAQ: VTGN - Get Free Report) is projected to release its Q2 2027 results before the market opens on Thursday, November 12th. Analysts expect the company to post earnings of…
benzinga.com Vistagen Intends To Adopt Incorporate Interim Assessments Of Fasedienol's Effect Through eDiaries, Qualitative Patient Surveys In Phase 3 Trial Design After Type C Meeting With FDA Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry, today announced a regulatory update from its recent, productive…
globenewswire.com Vistagen Provides Regulatory Update Following Productive Type C Meeting with U.S. FDA on Phase 3 Development of Fasedienol for Social Anxiety Disorder Constructive feedback from FDA clarifies potential Phase 3 development path forward Constructive feedback from FDA clarifies potential Phase 3 development path forward
benzinga.com Vistagen Therapeutics Implements 31% Workforce Reduction On October 26, 2026; Workforce Reduction Expected To Save $3.20M In Salary And Benefits Annually On October 26, 2026, Vistagen Therapeutics, Inc. (the "Company") implemented a Board-approved reduction in workforce by approximately 31%, retaining core clinical, regulatory, technical, and corporate